The Liver is Hot in Biotech. All Eyes on November
Recap - November is approaching, and the AASLD’s Liver Meeting conference the second week of the month, attracting a bevy of investors this year. The liver has become … Continue Reading
Read NowzFree
Latest Must-Knows for Arrowhead Research
Insights - Arrowhead Research (ARWR) presented on Friday at Biocentury’s Newsmakers in the Biotech Industry conference. Investors are paying close attention given an important data event in November for ARC-520 … Continue Reading
Read Now
Over-Optimism Comes Back to Bite AcelRx Following FDA Meeting
Insights - Following a teleconference with the FDA, AcelRx Pharmaceuticals (ACRX) says that a resubmission of the Zalviso New Drug Application won’t occur until the first quarter … Continue Reading
Read Now
Acorda Puts Cash Trove to Use, Cynapsus Feels the Effects
Insights - Acorda Therapeutics (NASDAQ:ACOR) will acquire privately-held Civitas Therapeutics for $525 million in cash, adding the phase 3-ready treatment for OFF episodes in Parkinson’s Disease (PD), CVT-301, to its roster … Continue Reading
Read Now
Merrimack and Baxter Tie Up for Pancreatic Cancer Drug
Insights - Merrimack Pharmaceuticals (NASDAQ:MACK) and Baxter (NYSE:BAX) have climbed into bed on MM-398, Merrimack’s drug candidate for the treatment of metastatic pancreatic cancer, in a licensing deal worth … Continue Reading
Read Now
Titan Pharma Halfway Through Pivotal Trial, but Check Out that Trading Range
Insights - Titan Pharmaceuticals (TTNP) announced on Tuesday that enrollment in a final phase 3 trial of Probuphine has reached the halfway mark, and that the company continues … Continue Reading
Read Now
Threshold Gets Past First Hurdle; Real Event is Next Year
Insights - A phase 3 trial of Threshold Pharma’s (THLD) hypoxia-targeting therapeutic, TH-302, in soft-tissue sarcoma will continue as planned following an interim analysis of the ongoing … Continue Reading
Read Now